Evidence map›Paper›PMID 37857712›Full record

ArticleNature medicine2023

AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial.

Birgit Geoerger, Xavier Paoletti, Francisco Bautista, Susanne A Gatz, Lynley V Marshall, Nicolas André, Pablo Berlanga, Stephane Ducassou, Claudia Pasqualini, Michela Casanova and 12 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Birgit GeoergerGustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France. birgit.geoerger@gustaveroussy.fr.ORCID 0000-0003-4361-3643
Xavier PaolettiGustave Roussy Cancer Campus, Biostatistics and Epidemiology Unit, INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, France.ORCID 0000-0002-1250-0040
Francisco BautistaHospital Niño Jesús, Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Madrid, Spain.
Susanne A GatzInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-6438-9778
Lynley V MarshallRoyal Marsden Hospital & The Institute of Cancer Research, Paediatric and Adolescent Oncology Drug Development Unit, London, UK.
Nicolas AndréHôpital de la Timone, Department of Pediatric Oncology, AP-HM; UMR INSERM 1068, CNRS UMR 7258, Aix Marseille Université U105, Marseille Cancer Research Center (CRCM); Metronomics Global Health Initiative, Marseille, France.ORCID 0000-0002-6786-4968
Pablo BerlangaGustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.
Stephane DucassouCentre Hospitalier Universitaire Pellegrin-Hôpital des Enfants, Bordeaux, France.
Claudia PasqualiniGustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.
Michela CasanovaFondazione IRCCS Istituto Nazionale dei Tumori, Pediatric Oncology Unit, Milan, Italy.
C Michel ZwaanPrincess Máxima Center for Pediatric Oncology, Utrecht, and Erasmus MC, Rotterdam, the Netherlands.
Karsten NysomRigshospitalet, Department of Paediatrics and Adolescent Medicine, Copenhagen, Denmark.
Jonathan RubinoGustave Roussy Cancer Campus, Clinical Research Direction, Université Paris-Saclay, Villejuif, France.
Delphine Vuillier-Le GoffGustave Roussy Cancer Campus, Clinical Research Direction, Université Paris-Saclay, Villejuif, France.
Baptiste ArchambaudGustave Roussy Cancer Campus, Biostatistics and Epidemiology Unit, INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, France.
Samuel AbbouGustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.
Gudrun SchleiermacherINSERM U830 RTOP (Recherche Translationelle en Oncologie Pédiatrique) and SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.ORCID 0000-0002-0133-5879
Christelle DufourGustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.ORCID 0000-0001-5993-8077
Patricia BlancAssociation Imagine for Margo, Paris, France.
Natalie Hoog-LabouretInstitut National du Cancer, Boulogne, France.
Agnes BuzynInstitut National du Cancer, Boulogne, France.
Gilles VassalGustave Roussy Cancer Campus, Clinical Research Direction, Université Paris-Saclay, Villejuif, France.

Funding

Cancer Research UK 24522
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsAdaptive Clinical Trials as TopicClinical Trials as TopicHumans

Identifiers

PMID37857712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.